Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University Hospitals Bristol and Weston NHS Foundation Trust
Merck Sharp & Dohme LLC
University of California, Davis
Brigham and Women's Hospital
Janssen Research & Development, LLC
Jonsson Comprehensive Cancer Center
Incyte Corporation
G1 Therapeutics, Inc.
Incyte Corporation
Incyte Corporation
Incyte Corporation
MacroGenics
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Aprea Therapeutics
Thomas Jefferson University
Spanish Oncology Genito-Urinary Group
European Association of Urology Research Foundation
Bayer
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany